Family Medicine Doctors in Willoughby, OH Accepting Medicare

5 Family Medicine doctors found. Showing 1 - 5

Dr. Ming Huei Phillip Chiang, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 36001 Euclid Ave, B4, Willoughby, OH 44094 Phone: 440-946-5151    Fax: 440-946-8841

Tam Pham Mclean, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5105 Som Center Rd, #106, Willoughby, OH 44094 Phone: 440-953-5740    Fax: 440-953-5741

Dr. Anne Margaret Rex, DO Family Medicine - Sports Medicine Medicare: Accepting Medicare Assignments Practice Location: 34820 Chardon Rd, Willoughby, OH 44094 Phone: 440-944-5700    Fax: 440-944-7849

Maita Louise Jarkewicz, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 4661 Maple St, Willoughby, OH 44094 Phone: 440-724-7471

Miss Christina Maria Chandler, REGISTERED NURSE Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 39021 Signature Circle, Willoughby, OH 44094 Phone: 216-533-9414

News Archive

Merck commences Stimuvax Phase 3 trial in Asian patients with NSCLC

Oncothyreon Inc. today announced that Merck KGaA of Darmstadt, Germany, has initiated a Phase 3 trial of Stimuvax(R) (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer (NSCLC). The trial, named INSPIRE (Stimuvax trial In Asian NSCLC Patients: Stimulating Immune Response), is anticipated to enroll approximately 420 patients in China, Hong Kong, South Korea, Singapore and Taiwan.

Visualization of SARS-CoV-2 RNA by fluorescence in situ hybridization probes

A team of scientists from France has recently designed fluorescence in situ hybridization probes (CoronaFISH) to visualize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in infected cells. A detailed description of the probe design, validation, and application is currently available on the bioRxiv preprint server.

Positive results from BioCardia's Helical Infusion System Phase 1/2 trial on ischemic cardiomyopathy

BioCardia, Inc., focused on regenerative biologic therapies for cardiovascular disease, today announced positive results from a Phase 1/2 heart failure trial using the Company's Helical Infusion System, comprising the Helical Infusion System Catheter and Morph Vascular Access Catheter, to deliver allogeneic, or "off-the-shelf," and autologous, or from the treated patient, mesenchymal (adult) stem cells (MSCs) via transendocardial injection.

Rheumatology providers and patient advocates urge lawmakers to address healthcare challenges

The American College of Rheumatology will hold its first virtual Advocates for Arthritis event on Tuesday, Sept. 15, where more than 120 rheumatologists, rheumatology health professionals, and patient advocates will meet with lawmakers via video to discuss the healthcare challenges they are facing in the midst of COVID-19.

Read more Medical News

› Verified 9 days ago